Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at about $2.2 billion. Sanofi said it will pay $15.50 per share for Dynavax, representing a premium of roughly 39% to the company’s closing price
Italy has become the latest European regulator to challenge how Big Tech is integrating artificial intelligence into widely used digital platforms. This week, the country’s antitrust authority ordered Meta Platforms to suspend certain WhatsApp contractual terms while it investigates whether the company abused its dominant position. The case centres on AI chatbots and whether recent
The Curve DAO community has rejected a proposal that sought to provide significant financial backing to its main development entity, Swiss Stake. The vote marks the latest governance decision within the Curve Finance ecosystem and comes as the protocol’s native token continues to show resilience around the $0.37 level. According to details from the vote,
The Strategy stock price continued its freefall this month and is now hovering at its lowest level since September last year. MSTR stock has plunged by over 70% from its highest level in 2024, even as the S&P 500 and the Nasdaq 100 indices jumped to a record high. Strategy enterprise NAV is about to
The United States has sharply escalated its confrontation with Europe over digital regulation, imposing visa sanctions on former European Union officials and leaders of anti-disinformation groups in a move that has drawn swift condemnation from across the Atlantic. The sanctions, announced on Tuesday by the US State Department, target a former senior EU official and
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in January 2026. The decision comes as more Americans are likely to try the medications in pill form rather than injections, owing to the lower cost and many
Ethereum’s price has struggled to break above the $3,000 level over the past week, weighed down by continued outflows from spot Bitcoin and Ethereum exchange-traded funds. That pattern has persisted into this week, with both BTC and ETH funds seeing redemptions as investors adjust portfolios toward year-end. Against this backdrop, Ethereum remains range-bound below the
US stocks held steady on Christmas Eve, with the broad market opening virtually flat. The Dow edged marginally higher, while the Nasdaq Composite matched the S&P’s sluggish performance in a shortened trading session marked by thin holiday volumes and cautious investor positioning heading into the year-end break. The S&P 500 closed at an all-time high
Shares of Agios Pharmaceuticals surged nearly 15% in premarket trading on Wednesday after the US Food and Drug Administration approved an expanded use of its drug mitapivat, strengthening investor optimism around the company’s growth prospects. The approval allows mitapivat to be used to treat anemia in patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia,
Latin America’s steel industry is under increasing strain as surging imports from China squeeze local markets and stall growth, despite the region’s rising demand for building materials. Industry officials argue that domestic producers face an uneven playing field, distorted by government subsidies and artificially low prices that favour Chinese steel. According to Ezequiel Tavernelli, president